According to Japanese pharmaceutical giant Kowa, the anti-parasite drug Ivermectin has an “antiviral” effect against omicrons and other COVID variants.
According to Reuters, the firm has been working closely with Tokyo’s Kitasato University.
Reuters called the study “non-clinical” but the American Journal of Therapeutics published a meta-analysis of 15 clinical studies last June.
The AJT analysis was concluded:
Ivermectin can be used to reduce COVID-19 death rates by moderate certainty. Ivermectin may be used early in the clinical process to reduce the risk of severe disease. Ivermectin’s low cost and apparent safety suggest that it will have a significant impact globally on the SARS-CoV-2 pandemic.
Joe Rogan, a podcast star, took Ivermectin to treat COVID. The well-known positive results were well-known. NBC News called it a “widely discredited” drug.
The same AJT analysis noted that “Ivermectin had exhibited antiviral activities against a wide variety of RNA and certain DNA viruses,” which seems to be in line with today’s news from Japan.
Rogan also received unapproved monoclonal antibody treatments to combat the infection. The FDA ordered Florida to close all monoclonal treatment centers last week.
Florida is in the middle of the pack with 302 COVID-related death per 100,000 residents. This is despite Florida having the highest number of elderly citizens — those most at risk from COVID — in any state.
According to Reuters, Kowa is currently conducting clinical studies on Ivermectin.
